FOXD1 and sarcoma: In terms of FOXD1 dysregulation, FOXD1 overexpression was identified in esophageal cancer (ESCA), lymphoid neoplasm large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), sarcoma (SARC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and uterine carcinosarcoma (UCS) (Figure 5).